Comparative Pharmacology
Head-to-head clinical analysis: RAUWILOID versus SERPIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUWILOID versus SERPIVITE.
RAUWILOID vs SERPIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Category C
Category C
Antihypertensive
Antihypertensive